



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/00, 31/40, 31/445		A1	(11) International Publication Number: WO 94/03162 (43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/EP93/02041			(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 30 July 1993 (30.07.93)			
(30) Priority data: 9216380.7 31 July 1992 (31.07.92) GB			
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventor; and			
(75) Inventor/Applicant (for US only) : BIRCH, Phillip, John [GB/GB]; Glaxo Group Research Limited, Park Road, Ware, Hertfordshire SG12 0DP (GB).			
(74) Agents: FILLER, Wendy, Anne et al.; Glaxo Holdings plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			

(54) Title: MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE**(57) Abstract**

The invention relates to a new medical use for compounds having selective agonist activity at 5-HT₁-like receptors and to pharmaceutical compositions containing them. In particular it relates to a new medical use of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide and physiologically acceptable salts and solvates thereof for the treatment or prevention of elevated intraocular pressure, in particular glaucoma.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BC	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRACULAR PRESSURE

This invention relates to a new medical use for compounds having selective agonist activity at 5-HT₁-like receptors and to pharmaceutical compositions containing them. In particular it relates to a new medical use of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide and physiologically acceptable salts and solvates thereof.

5-HT₁-like receptors are located, for example, in the dog saphenous vein and the 5-HT₁-like receptor agonists with which the present invention is concerned contract the dog saphenous vein. Such compounds may therefore be identified by their contractile effect on the dog isolated saphenous vein strip as described, for example, by Apperley *et al.*, Br. J. Pharmacol., 68, 215-224 (1980). Compounds which are selective 5-HT₁-like receptor agonists have also been found to selectively constrict the carotid arterial bed of the anaesthetised dog.

A variety of compounds which selectively constrict the dog isolated saphenous vein strip and which constrict the carotid arterial bed of the anaesthetised dog have been described in the art. These include indole derivatives such as those disclosed *inter alia* in published British Patent Specifications Nos. 2082175, 2081717, 2083463, 2124210, 2150932, 2162522, 2168347, 2168973, 2185020, 2186874, 2191488, 2208646, published European Patent Specifications Nos. 147107, 237678, 242939, 244085, 225726, 254433, 303506, 313397, 354777, 382570, 464558, 506363, 506369, 450238, 451022, 451008, 478954, 438230, 494774, 497512, 501568 and published International patent application Nos. WO92/11013, WO92/11014, WO92/06973, WO93/00086, WO92/13856, WO93/00094, WO91/18897 and WO93/00333.

The compounds disclosed in the aforementioned patent specifications have been described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature, in particular migraine and related disorders such as cluster headache.

We now find that such compounds are also of use in the treatment of certain ocular disorders.


Glaucoma is a serious progressive clinical condition caused by an imbalance in the flow of intraocular fluids, leading to elevated intraocular pressure, optic nerve degeneration and eventual blindness. Current medical therapy for glaucoma is dominated by pharmacological agents which act by reducing the flow of fluid into the ocular chamber, for example beta blockers, and the side-effect profiles of such drugs severely limit their clinical use. Thus, there is a real need to develop new medicines in this area of ophthalmic disease.

Surprisingly, compounds which are selective 5-HT₁-like receptor agonists reduce elevated intraocular pressure and are effective in the treatment of glaucoma.

According to one aspect of the invention we therefore provide a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof for use in the treatment or prevention of elevated intraocular pressure, in particular glaucoma e.g. high tension glaucoma and low tension glaucoma.

Particularly preferred compounds for use in the treatment or prevention of elevated intraocular pressure are 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide and N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide, especially 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide.

3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide, which may be represented by the formula (I)



and its physiologically acceptable salts and solvates are disclosed in GB 2162522. Numerous clinical studies have demonstrated the effectiveness of the compound of formula (I) (generic name sumatriptan) in migraineurs.

5 Thus, a particularly preferred aspect the present invention provides the compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prevention of elevated intraocular pressure.

10 In an alternative or further aspect, the invention provides a method of treatment of a mammal, including man, suffering from or susceptible to elevated intraocular pressure which comprises administering an effective amount of a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof.

15 It will be appreciated that whilst selective 5-HT₁-like receptor agonists will primarily be of use in the alleviation of established symptoms, prophylaxis is not excluded.

20 In a further aspect, the invention provides the use of a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prevention of elevated intraocular pressure.

25 A further aspect of the invention provides pharmaceutical compositions for the treatment or prevention of elevated intraocular pressure comprising as active ingredient a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof.

In a preferred aspect the invention provides a pharmaceutical composition for topical administration to the eye which comprises as active ingredient a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier or excipient.

Suitable physiologically acceptable salts of selective 5-HT₁-like receptor agonists include acid addition salts formed with organic or inorganic acids for example hydrochlorides, hydrobromides, sulphates, nitrates, phosphates, formates, mesylates, citrates, benzoates, fumarates, maleates and succinates.

5 In a particularly preferred embodiment of the present invention, the selective 5-HT₁-like receptor agonist employed is the compound of formula (I) in the form of the succinate (1:1) salt or the hemisulphate (2:1) salt.

10 The compound for use according to the invention may be administered as the raw chemical comprising the active ingredient in an amount of from 0.1mg to 300mg.

15 Conveniently, the compound for use according to the invention may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Thus, the compound for use according to the invention may for example be formulated for oral, sub-lingual, buccal, parenteral, rectal or intranasal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose) or in a form suitable for topical administration, preferably for local application in the eye.

20 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically

acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid).

5 For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compound for use according to the invention may be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example by bolus injection or continuous 10 intravenous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, optionally with an added preservative.

The compositions for parenteral administration may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may 15 contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in dry form such as a powder, crystalline or freeze-dried solid for constitution with a suitable vehicle, e.g. sterile pyrogen-free water or isotonic saline before use. They may be presented, for example, in sterile ampoules or vials.

20 The compound for use according to the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glyceride.

Tablets for sub-lingual administration may be formulated in a conventional manner.

25 For intranasal administration the compound for use according to the invention may be used, for example, as a liquid in the form of, for example, a solution, suspension or emulsion, presented in the form of a spray or drops, or as a

powder. Preferably the preparation for intranasal administration is delivered in the form of a spray or aerosol from an insufflator or from a pressurised pack or nebuliser with the use of a suitable propellant.

For administration by inhalation the compound for use according to the invention is conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

For topical administration the pharmaceutical compositions may be liquids, for example solutions, suspensions or emulsions presented in the form of creams, gels or drops suitable for local application to the eye.

It will be appreciated that the precise dose administered will depend on the age and condition of the patient and the frequency and route of administration and will be at the ultimate discretion of the attendant physician. The compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 4 times per day.

A proposed dose of the active ingredient for use according to the invention for oral, sub-lingual, parenteral, buccal, rectal, intranasal or topical administration to man (of approximately 70kg bodyweight) for the treatment of glaucoma may be 0.1 to 300mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

For oral administration a unit dose will preferably contain from 2 to 200mg, more preferably 20 to 100mg of the active ingredient. Dosages of the compound for

7a

use according to the invention for rectal or sub-lingual administration are similar to those for oral administration. A unit dose for parenteral administration will preferably contain 0.1 to 15mg, more preferably 0.2 to 10mg of the active ingredient. For intranasal administration a unit dose may contain 1 to 100mg, 5 preferably 2 to 50mg of the active ingredient.

Aerosol formulations are preferably arranged so that each metered dose or 'puff' delivered from a pressurised aerosol contains 0.2mg to 2mg of a compound for use according to the invention. Capsules and cartridges suitable for use in an insufflator or an inhaler may contain 0.2mg to 20mg of a compound 10 of the invention. The overall daily dose by inhalation with an aerosol will be within the range 1mg to 100mg. Administration may be several times daily, for example from 2 to 8 times, giving for example 1, 2 or 3 doses each time.

Claims

1. Use of a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prevention of elevated intraocular pressure.
5
2. Use as claimed in claim 1 wherein the medicament is for the treatment or prevention of glaucoma.
- 10 3. Use as claimed in claim 1 or claim 2 wherein the selective 5-HT₁-like receptor agonist is 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide.
- 15 4. Use as claimed in claim 3 wherein the selective 5-HT₁-like receptor agonist is 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide.
- 20 5. Use as claimed in any one of claims 1 to 4 wherein the medicament is adapted for oral administration.
- 25 6. Use as claimed in any one of claims 1 to 4 wherein the medicament is adapted for topical administration to the eye.
- 30 7. Use as claimed in any one of claims 1 to 6 wherein the medicament contains a unit dose of 0.1 to 300mg of a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof.
8. A selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof for use in the treatment or prevention of elevated intraocular pressure.
35
9. A medicament for the treatment or prevention of elevated intraocular pressure comprising, as active ingredient, a selective 5-HT₁-like receptor agonist or a physiologically acceptable salt or solvate thereof.

10. A method of treatment of a mammal, including man, suffering from or
susceptible to elevated intraocular pressure which comprises
administering an effective amount of a selective 5-HT₁-like receptor
agonist or a physiologically acceptable salt or solvate thereof.

5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 93/02041

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K31/00 A61K31/40 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	EXP. EYE RES. vol. 57, no. 2 , August 1993 pages 209 - 216 N.L.BARNETT ET AL. 'The Presence of Serotonin (5-HT1) Receptors Negatively Coupled to Adenylate Cyclase in Rabbit and Human Iris-Ciliary Processes' see the whole document --- J.NEUROCHEM. vol. 53, no. 3 , September 1989 pages 686 - 691 A.B.TOBIN ET AL. 'Evidence for the Presence of Serotonin Receptors Negatively Coupled to Adenylate Cyclase in the Rabbit Iris-Ciliary Body' see the whole document --- --- ---/--	1-10
X		1-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 December 1993

Date of mailing of the international search report

10.01.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Theuns, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/02041

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	INVEST. OPHTHALMOL. VIS. SCI. vol. 34, no. 10 , September 1993 pages 3035 - 3042 U. MEYER-BOTHLING ET AL. 'Topical Application of Serotonin or the 5-HT1-Agonist 5-CT Intraocular Pressure in Rabbits' see the whole document ---	1-10
X	AM.J.PHYSIOL. vol. 261, no. 6PT2 , December 1991 pages H1819 - H1827 A.ZSCHAUER ET AL. 'Serotonergic responses in rabbit ophthalmic artery: a pharmacological characterization' see the whole document ---	1-10
X	NEUROCHEM. INT. vol. 19, no. 4 , 1991 pages 407 - 411 N.N.OSBORNE ET AL. '5-HT1a RECEPTORS POSITIVELY COUPLED TO C-AMP FORMATION IN THE RABBIT RETINA' see the whole document ---	1-10
X	NEUROL.NEUROBIOL. vol. 49 , 1989 pages 159 - 175 N.N.OSBORNE ET AL. 'SEROTONIN RECEPTORS AND THEIR INVOLVEMENT IN Ca++ MOBILIZATION AND GLYCOGENOLYSIS IN THE RABBIT RETINA' see the whole document ---	1-10
X	VIS.NEUROSCI. vol. 8, no. 3 , March 1992 pages 213 - 218 S.C.MANGEL ET AL. 'The effects of serotonin drugs on horizontal and ganglion cells in the rabbit retina' see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/02041

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 10 is directed to a method of treatment of the human animal body, the search has been based on the alleged effects of the compounds.
2. Claims Nos.: 1-2, 5-10 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The meaning of the expression "a selective 5-HT1-like receptor agonist" is not clear. The search consequently was limited to the use of the compounds mentioned by name in the claims.
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.